Skip to main content

Table 1 Immunotherapy of melanoma B16-F10 based on the synergy of R-848 and mannan-SMCC. Further improvement using poly(I:C) and anchored L. monocytogenes. Re-transplantation

From: Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model

Initial treatment

Number of survived mice

Group (see Fig. 4b)

Number of successful re-transplantations

L. monocytogenes-SMCC + R-848 + mannan-SMCC

5

b

1

L. monocytogenes-SMCC + R-848 + poly(I:C) + mannan-SMCC

5

c

0

R-848 + mannan-SMCC

2

d

2

R-848 + poly(I:C) + mannan-SMCC

1

e

0

  1. Re-transplantation of mice that survived in experiment shown in Fig. 4 was performed on day 120. All surviving mice were inoculated again with B16-F10 (4 × 105 melanoma cells/mouse s.c.)